Comparison of RNases and toxins upon injection into Xenopus oocytes.
Several toxins abolish cellular protein synthesis by attacking specific sites in 28 S RNA. One of these toxins, alpha-sarcin, is an RNase that also cleaves nonspecifically on the 3' side of purines in deproteinized RNA. Several other RNases were injected into Xenopus oocytes, examined for their ability to abolish protein synthesis, and compared with alpha-sarcin and ricin. Surprisingly, pancreatic RNase A or B abolished oocyte protein synthesis at concentrations (approximately 0.03 nM) comparable to, or lower than, the amount of alpha-sarcin (approximately 2 nM) or ricin (approximately 0.07 nM) required to abolish protein synthesis. RNases S and T1 only inhibited oocyte protein synthesis when used at concentrations approximately 10 x higher than RNase A whereas RNases C, T2, U2, and nuclease P1 required concentrations approximately 100 times higher than RNase A to abolish protein synthesis. There was a direct correlation between the degradation of oocyte RNA and the inhibition of protein synthesis. The RNase inhibitors RNasin and Inhibit-Ace injected into the oocyte both prevented RNase A from hydrolyzing oocyte rRNA and abolishing protein synthesis. Enzymatically inactive oxidized RNase A did not inhibit protein synthesis when injected into the oocyte. None of the RNases or alpha-sarcin abolished protein synthesis when added to oocyte extracellular medium. Angiogenin is a human plasma protein that induces blood vessel formation in chick embryos, has 35% amino acid identity with RNase A, and cleaves 18 S and 28 S RNA in rabbit reticulocyte lysates (St. Clair, D. K., Rybak, S. M., Riordan, J. F. & Vallee, B. L. (1988) Biochemistry 27, 7263-7268, and references therein). Recombinant angiogenin injected into oocytes abolished protein synthesis, and this toxic effect was inhibited by RNasin but was not inhibited by Inhibit-Ace. Unlike RNase A and the other nucleases that hydrolyzed cellular rRNA, no cleavage of 18 or 28 S RNA by recombinant angiogenin was seen at concentrations 100 x greater than necessary to abolish protein synthesis. Recombinant angiogenin must selectively attack specific RNA(s) or another target in the cell.
Biochemistry Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892.
S K
SK
Saxena
S M
SM
Rybak
G
G
Winkler
H M
HM
Meade
P
P
McGray
R J
RJ
Youle
E J
EJ
Ackerman
D000818:Animals; D004167:Diphtheria Toxin / Q000633:toxicity; D004722:Endoribonucleases; D005656:Fungal Proteins / Q000633:toxicity; D008845:Microinjections; D009865:Oocytes; D011500:Protein Synthesis Inhibitors / Q000633:toxicity*; D011506:Proteins / Q000494:pharmacology; D012339:RNA, Ribosomal, 28S / Q000378:metabolism; D012259:Ribonuclease, Pancreatic; D012260:Ribonucleases / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000633:toxicity*; D012276:Ricin / Q000633:toxicity; D014118:Toxins, Biological / Q000008:administration & dosage*; D014982:Xenopus laevis
D004167:Diphtheria Toxin; D005656:Fungal Proteins; D011500:Protein Synthesis Inhibitors; D011506:Proteins; D012339:RNA, Ribosomal, 28S; D014118:Toxins, Biological; C014801:alpha-sarcin; D012276:Ricin; D004722:Endoribonucleases; D012260:Ribonucleases; C046366:angiogenin; D012259:Ribonuclease, Pancreatic